Dr. James D. Griffin

Dr. James D. Griffin, MD, is a renowned hematologist-oncologist and physician-scientist whose career has been dedicated to advancing the molecular understanding and treatment of leukemia. He serves as Professor of Medicine at Harvard Medical School and Director of the Medical Oncology Division at Dana-Farber Cancer Institute. Dr. Griffin earned his medical degree from Harvard Medical School, completed his internal medicine residency at Massachusetts General Hospital, and trained as a medical oncology fellow at Dana-Farber Cancer Institute. He is board-certified in Internal Medicine and Medical Oncology.

Dr. Griffin’s groundbreaking research focuses on the role of tyrosine kinases, including FLT3 and KIT, in the pathogenesis of acute myeloid leukemia (AML) and other hematologic malignancies. His work has been central to the development and clinical adoption of targeted kinase inhibitors, which have transformed the treatment landscape for these diseases. He has authored over 300 peer-reviewed publications and has played a pivotal role in translating laboratory discoveries into effective clinical therapies.

As a leader in academic oncology, Dr. Griffin has mentored generations of clinician-scientists, many of whom now direct leukemia research programs worldwide. He serves on national and international advisory committees, contributes to NIH review panels, and is active in cooperative group research initiatives. Through his dual commitment to scientific discovery and patient care, Dr. James D. Griffin continues to influence the direction of leukemia research and treatment strategies globally.